BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance.  The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324. 

"The Phase 1 clinical trial of BGB324 will provide the opportunity to demonstrate the safety of BGB324 and evaluate clinical biomarker and pharmacodynamic assays the company has also developed." stated Richard Godfrey, CEO of BerGenBio. "Our extensive preclinical data suggest that BGB324 has wide therapeutic potential to address a range of clinically challenging cancers and the growing problem of acquired drug-resistance".